Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Lasers Surg Med ; 41(9): 686-96, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19802891

ABSTRACT

BACKGROUND AND OBJECTIVE: In a recently completed pilot clinical study at Roswell Park Cancer Institute, patients with superficial basal cell carcinoma (sBCC) received topical application of 20% 5-aminolevulinic acid (ALA) and were irradiated with 633 nm light at 10-150 mW cm(-2). Protoporphyrin IX (PpIX) photobleaching in the lesion and the adjacent perilesion normal margin was monitored by fluorescence spectroscopy. In most cases, the rate of bleaching slowed as treatment progressed, leaving a fraction of the PpIX unbleached despite sustained irradiation. To account for this feature, we hypothesized a decrease in blood flow during ALA-photodynamic therapy (PDT) that reduced the rate of oxygen transported to the tissue and therefore attenuated the photobleaching process. We have performed a detailed analysis of this hypothesis. STUDY DESIGN/MATERIALS AND METHODS: We used a comprehensive, previously published mathematical model to simulate the effects of therapy-induced blood flow reduction on the measured PpIX photobleaching. This mathematical model of PDT in vivo incorporates a singlet-oxygen-mediated photobleaching mechanism, dynamic unloading of oxygen from hemoglobin, and provides for blood flow velocity changes. It permits simulation of the in vivo photobleaching of PpIX in this patient population over the full range of irradiances and fluences. RESULTS: The results suggest that the physiological equivalent of discrete blood flow reductions is necessary to simulate successfully the features of the bleaching data over the entire treatment fluence regime. Furthermore, the magnitude of the blood flow changes in the normal tissue margin and lesion for a wide range of irradiances is consistent with a nitric-oxide-mediated mechanism of vasoconstriction. CONCLUSION: A detailed numerical study using a comprehensive PDT dosimetry model is consistent with the hypothesis that the observed trends in the in vivo PpIX photobleaching data from patients may be explained on the basis of therapy-induced blood flow reductions at specific fluences.


Subject(s)
Aminolevulinic Acid/pharmacology , Carcinoma, Basal Cell/blood supply , Photobleaching , Photochemotherapy , Photosensitizing Agents/pharmacology , Skin Neoplasms/blood supply , Carcinoma, Basal Cell/metabolism , Carcinoma, Basal Cell/therapy , Humans , Models, Cardiovascular , Protoporphyrins/pharmacokinetics , Regional Blood Flow/drug effects , Regional Blood Flow/radiation effects , Skin Neoplasms/metabolism , Skin Neoplasms/therapy , Spectrometry, Fluorescence
2.
Clin Cancer Res ; 15(13): 4460-6, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19549769

ABSTRACT

PURPOSE: Numerous preclinical studies have shown that local photodynamic therapy (PDT) of tumors enhances systemic antitumor immunity. However, other than single-case and anecdotal reports, this phenomenon has not been examined following clinical PDT. To determine whether PDT in a clinical setting enhances systemic recognition of tumor cells, we examined whether PDT of basal cell carcinoma resulted in an increased systemic immune response to Hip1, a tumor antigen associated with basal cell carcinoma. EXPERIMENTAL DESIGN: Basal cell carcinoma lesions were either treated with PDT or surgically removed. Blood was collected from patients immediately before or 7 to 10 days following treatment. Peripheral blood leukocytes were isolated from HLA-A2-expressing patients and reactivity to a HLA-A2-restricted Hip1 peptide was measured by INF-gamma ELISpot assay. RESULTS: Immune recognition of Hip1 increased in patients whose basal cell carcinoma lesions were treated with PDT. This increase in reactivity was significantly greater than reactivity observed in patients whose lesions were surgically removed. Patients with superficial lesions exhibited greater enhancement of reactivity compared with patients with nodular lesions. Immune reactivity following PDT was inversely correlated with treatment area and light dose. CONCLUSIONS: These findings show for the first time that local tumor PDT can enhance systemic immune responses to tumors in patients, and validate previous preclinical findings.


Subject(s)
Antigens, Neoplasm/immunology , Carcinoma, Basal Cell/drug therapy , Carcinoma, Basal Cell/immunology , Immunity, Cellular/physiology , Photochemotherapy , Skin Neoplasms/drug therapy , Skin Neoplasms/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Amino Acid Sequence , Child , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/immunology , DNA-Binding Proteins/metabolism , Epitope Mapping , Female , HLA-A2 Antigen/metabolism , Humans , Male , Middle Aged , Peptide Fragments/analysis , Peptide Fragments/immunology , Peptide Fragments/metabolism , Protein Binding/immunology , Up-Regulation/immunology , Young Adult
4.
Bioconjug Chem ; 20(2): 274-82, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19191565

ABSTRACT

Two positional isomers of purpurinimide, 3-[1'-(3-iodobenzyloxyethyl)] purpurin-18-N-hexylimide methyl ester 4, in which the iodobenzyl group is present at the top half of the molecule (position-3), and a 3-(1'-hexyloxyethy)purpurin-18-N-(3-iodo-benzylimide)] methyl ester 5, where the iodobenzyl group is introduced at the bottom half (N-substitued cyclicimide) of the molecule, were derived from chlorophyll-a. The tumor uptake and phototherapeutic abilities of these isomers were compared with the pyropheophorbide analogue 1 (lead compound). These compounds were then converted into the corresponding 124I-labeled PET imaging agents with specific activity >1 Ci/micromol. Among the positional isomers 4 and 5, purpurinimide 5 showed enhanced imaging and therapeutic potential. However, the lead compound 1 derived from pyropheophorbide-a exhibited the best PET imaging and PDT efficacy. For investigating the overall lipophilicity of the molecule, the 3-O-hexyl ether group present at position-3 of purpurinimide 5 was replaced with a methyl ether substituent, and the resulting product 10 showed improved tumor uptake, but due to its significantly higher uptake in the liver, spleen, and other organs, a poor tumor contrast in whole-body tumor imaging was observed.


Subject(s)
Anthraquinones/therapeutic use , Chlorophyll/therapeutic use , Iodobenzenes/chemistry , Photochemotherapy , Animals , Anthraquinones/chemistry , Anthraquinones/pharmacokinetics , Chlorophyll/chemistry , Chlorophyll/pharmacokinetics , Chlorophyll A , Iodine Radioisotopes/chemistry , Isomerism , Mice , Neoplasms/diagnostic imaging , Neoplasms/drug therapy , Neoplasms/metabolism , Photosensitizing Agents/chemistry , Photosensitizing Agents/pharmacokinetics , Photosensitizing Agents/therapeutic use , Positron-Emission Tomography , Tissue Distribution
5.
J Med Chem ; 52(2): 445-55, 2009 Jan 22.
Article in English | MEDLINE | ID: mdl-19090663

ABSTRACT

In our present study, 3-(1(')-m-iodobenzyloxyethyl)pyropheophorbide-a methyl ester 1, 3-(1'-m-iodobenzyloxyethyl)-17(2)-{(2-deoxy)glucose}pyropheophorbide-a 2, and 3-(1'-m-iodobenzyloxyethyl)-17(2)-{(1-deoxy)galactose}pyropheophorbide-a 3 were synthesized and converted into the corresponding (124)I-labeled analogues by reacting the intermediate trimethyltin analogues with Na(124)I. Photosensitizers 1-3 were evaluated for the PDT efficacy in C3H mice bearing RIF tumors at variable doses and showed a significant long-term tumor cure. Among the compounds investigated, the non-carbohydrate analogue 1 was most effective. These results were in contrast to the in vitro data, where compared to the parent analogue the corresponding galactose and glucose derivatives showed enhanced cell kill. Among the corresponding (124)I-labeled analogues, excellent tumor images were obtained from compound 1 in both tumor models (RIF and Colon-26) and the best tumor contrast was observed at 72 h after injection. Conjugating a glucose moiety to photosensitizer 1 initially diminished its tumor uptake, whereas with time the corresponding galactose analogue showed improved tumor contrast.


Subject(s)
Chlorophyll/analogs & derivatives , Galactose/chemistry , Glucose/chemistry , Iodine Radioisotopes/therapeutic use , Photochemotherapy , Positron-Emission Tomography/methods , Animals , Chlorophyll/chemistry , Chlorophyll/pharmacokinetics , Chlorophyll/therapeutic use , Chromatography, High Pressure Liquid , Magnetic Resonance Spectroscopy , Mass Spectrometry , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Spectrophotometry, Ultraviolet , Tissue Distribution
6.
Int J Dermatol ; 48(11): 1236-45, 2009 Nov.
Article in English | MEDLINE | ID: mdl-20064185

ABSTRACT

BACKGROUND: Data suggest that photodynamic therapy using topical methyl aminolevulinate (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell carcinoma (BCC). In the studies described here, we investigated the histologic response, tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (or= 50% reduction in greatest diameter) at 3 months were re-treated (21%). Treatment sites were excised at 3 months (clinical nonresponders) or 6 months (clinical responders) after the last treatment. RESULTS: Histologically verified lesion complete response rates were higher with MAL PDT than with placebo [73% (55/75) vs. 27% (20/75)]. Treatment was most effective for facial lesions (89% complete response). Cosmetic outcome was good or excellent in 98% of evaluable, completely responding lesions treated with MAL PDT. CONCLUSION: Although longer follow-up studies are required, these promising data indicate the potential of topical MAL PDT as a noninvasive treatment alternative for nodular BCC.


Subject(s)
Aminolevulinic Acid/analogs & derivatives , Carcinoma, Basal Cell/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Aminolevulinic Acid/adverse effects , Aminolevulinic Acid/therapeutic use , Carcinoma, Basal Cell/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Photochemotherapy/adverse effects , Photosensitizing Agents/adverse effects , Prospective Studies , Skin Neoplasms/pathology , Treatment Outcome
7.
Clin Cancer Res ; 14(14): 4475-83, 2008 Jul 15.
Article in English | MEDLINE | ID: mdl-18628462

ABSTRACT

PURPOSE: In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain. The rate of singlet-oxygen production depends on the product of irradiance and photosensitizer and oxygen concentrations. High irradiance and/or photosensitizer levels cause inefficient treatment from oxygen depletion in preclinical models. EXPERIMENTAL DESIGN: Self-sensitized photobleaching of protoporphyrin IX (PpIX) fluorescence was used as a surrogate metric for photodynamic dose. We developed instrumentation measuring fluorescence and reflectance from lesions and margins during treatment at 633 nm with various irradiances. When PpIX was 90% bleached, irradiance was increased to 150 mW/cm(2) until 200 J/cm(2) were delivered. Pain was monitored. RESULTS: In 33 superficial basal cell carcinomas in 26 patients, photobleaching efficiency decreased with increasing irradiance above 20 mW/cm(2), consistent with oxygen depletion. Fluences bleaching PpIX fluorescence 80% (D80) were 5.7 +/- 1.6, 4.5 +/- 0.3, 7.5 +/- 0.8, 7.4 +/- 0.3, 12.4 +/- 0.3, and 28.7 +/- 7.1 J/cm(2), respectively, at 10, 20, 40, 50, 60 and 150 mW/cm(2). At 20-150 mW/cm(2), D80 doses required 2.5-3.5 min; times for the total 200 J/cm(2) were 22.2-25.3 min. No significant pain occurred up to 50 mW/cm(2); pain was not significant when irradiance then increased. Clinical responses were comparable to continuous 150 mW/cm(2) treatment. CONCLUSIONS: Photodynamic therapy with topical delta-aminolevulinic acid using approximately 40 mW/cm(2) at 633 nm is photodynamically efficient with minimum pain. Once PpIX is largely photobleached, higher irradiances allow efficient, rapid delivery of additional light. Optimal fluence at a single low irradiance is yet to be determined.


Subject(s)
Aminolevulinic Acid/therapeutic use , Carcinoma, Basal Cell/drug therapy , Photobleaching , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Skin Neoplasms/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Basal Cell/physiopathology , Female , Humans , Male , Middle Aged , Pain/etiology , Pain Measurement , Photochemotherapy/adverse effects , Protoporphyrins/metabolism , Skin Neoplasms/physiopathology
8.
Nano Lett ; 7(9): 2835-42, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17718587

ABSTRACT

We report a novel nanoformulation of a photosensitizer (PS), for photodynamic therapy (PDT) of cancer, where the PS molecules are covalently incorporated into organically modified silica (ORMOSIL) nanoparticles. We found that the covalently incorporated PS molecules retained their spectroscopic and functional properties and could robustly generate cytotoxic singlet oxygen molecules upon photoirradiation. The synthesized nanoparticles are of ultralow size ( approximately 20 nm) and are highly monodispersed and stable in aqueous suspension. The advantage offered by this covalently linked nanofabrication is that the drug is not released during systemic circulation, which is often a problem with physical encapsulation. These nanoparticles are also avidly uptaken by tumor cells in vitro and demonstrate phototoxic action, thereby highlighting their potential in diagnosis and PDT of cancer.


Subject(s)
Drug Carriers/chemistry , Nanoparticles/chemistry , Neoplasms/drug therapy , Neoplasms/pathology , Photochemotherapy/methods , Photosensitizing Agents/administration & dosage , Silicon Dioxide/chemistry , Animals , Cell Line, Tumor , Cell Survival/drug effects , Crystallization/methods , Drug Compounding/methods , Humans , Materials Testing , Molecular Conformation , Nanoparticles/ultrastructure , Nanotechnology/methods , Organic Chemicals/chemistry , Particle Size , Photosensitizing Agents/chemistry
10.
J Natl Compr Canc Netw ; 5(5): 531-40, 2007 May.
Article in English | MEDLINE | ID: mdl-17509255

ABSTRACT

Photodynamic therapy (PDT) involves the administration of a photosensitizing drug and its subsequent activation by light at wavelengths matching the absorption spectrum of the photosensitizer. Because the skin is readily accessible to light-based therapies, PDT with systemic and particularly with topical agents has become important in treating cutaneous disorders. Topical PDT is indicated for treating actinic keratosis, superficial or thin non-melanoma skin cancer, including some cases of nodular basal cell carcinoma, and some cutaneous lymphomas. Advantages of aminolevulinic acid/methyl aminolevulinate PDT include the possibility of simultaneous treatment of multiple tumors and large surface areas, good cosmesis, and minimal morbidity, such as bleeding, scarring, or infection.


Subject(s)
Carcinoma, Basal Cell/drug therapy , Carcinoma, Squamous Cell/drug therapy , Photochemotherapy/methods , Skin Neoplasms/drug therapy , Bowen's Disease/drug therapy , Humans , Keratosis/drug therapy , Light , Lymphoma, B-Cell/drug therapy , Lymphoma, T-Cell, Cutaneous/drug therapy , Photosensitizing Agents/therapeutic use
12.
Clin Cancer Res ; 13(8): 2463-70, 2007 Apr 15.
Article in English | MEDLINE | ID: mdl-17438106

ABSTRACT

PURPOSE: The ATP-binding cassette protein ABCG2 (breast cancer resistance protein) effluxes some of the photosensitizers used in photodynamic therapy (PDT) and, thus, may confer resistance to this treatment modality. Tyrosine kinase inhibitors (TKI) can block the function of ABCG2. Therefore, we tested the effects of the TKI imatinib mesylate (Gleevec) on photosensitizer accumulation and in vitro and in vivo PDT efficacy. EXPERIMENTAL DESIGN: Energy-dependent photosensitizer efflux and imatinib mesylate's effects on intracellular accumulation of clinically used second- and first-generation photosensitizers were studied by flow cytometry in murine and human cells with and without ABCG2 expression. Effects of ABCG2 inhibition on PDT were examined in vitro using cell viability assays and in vivo measuring photosensitizer accumulation and time to regrowth in a RIF-1 tumor model. RESULTS: Energy-dependent efflux of 2-(1-hexyloxethyl)-2-devinyl pyropheophorbide-a (HPPH, Photochlor), endogenous protoporphyrin IX (PpIX) synthesized from 5-aminolevulenic acid, and the benzoporphyrin derivative monoacid ring A (BPD-MA, Verteporfin) was shown in ABCG2+ cell lines, but the first-generation multimeric photosensitizer porfimer sodium (Photofrin) and a novel derivative of HPPH conjugated to galactose were minimally transported. Imatinib mesylate increased accumulation of HPPH, PpIX, and BPD-MA from 1.3- to 6-fold in ABCG2+ cells, but not in ABCG2- cells, and enhanced PDT efficacy both in vitro and in vivo. CONCLUSIONS: Second-generation clinical photosensitizers are transported out of cells by ABCG2, and this effect can be abrogated by coadministration of imatinib mesylate. By increasing intracellular photosensitizer levels in ABCG2+ tumors, imatinib mesylate or other ABCG2 transport inhibitors may enhance efficacy and selectivity of clinical PDT.


Subject(s)
ATP-Binding Cassette Transporters/physiology , Neoplasm Proteins/physiology , Photochemotherapy , Photosensitizing Agents/therapeutic use , Piperazines/therapeutic use , Pyrimidines/therapeutic use , ATP Binding Cassette Transporter, Subfamily G, Member 2 , Antineoplastic Agents/therapeutic use , Benzamides , Carcinoma, Squamous Cell , Cell Line, Tumor , Combined Modality Therapy , Humans , Hypopharyngeal Neoplasms , Imatinib Mesylate , Photosensitizing Agents/antagonists & inhibitors , Protein-Tyrosine Kinases/antagonists & inhibitors
13.
Mol Pharm ; 4(3): 448-64, 2007.
Article in English | MEDLINE | ID: mdl-17373821

ABSTRACT

A lactose moiety was regioselectively introduced at various positions of N-hexyl-mesopurpurinimide (a class of chlorin containing a fused six-membered imide ring system, lambda(max): 700 nm) to investigate the effect of its presence and position on photosensitizing efficacy. The resulting novel structures produced a significant difference in in vitro and in vivo efficacy. Among the positional isomers in which the lactose moiety was introduced at positions 3, 8, and 12, the 3-lactose purpurin-18-N-hexylimide produced the best efficacy. Compared to these analogues, the lactose moiety joined with an amide bond at position 17(2), and with an N-benzyl group bearing a -C[triple bond]C- linkage at position 13(2) showed reduced in vitro/in vivo photosensitivity. A noticeable difference between lactose conjugates in cell uptake (RIF tumor cells) was observed at 3 and 24 h postincubation. Replacing the lactose (Galbeta1 --> 4Glc) with beta-galactose and glucose moieties at position 3 of purpurinimide produced an increase in both cell uptake and in in vitro efficacy, but with reduced in vivo efficacy. Sites of intracellular localization differed among photosensitizers with and without carbohydrate moieties. Molecular modeling shows favorable interactions of 3- and 12-lactose-purpurinimide analogues with both galectin-1 and galectin-3, but clear contributions were not found for the conjugate containing lactose moiety at position 8. In a comparative ELISA study of the lactose conjugates with free lactose, all carbohydrate-purpurinimides showed binding to both galectins with a significant variation between the batches of galectins.


Subject(s)
Carbohydrates/chemistry , Carbohydrates/pharmacology , Photosensitizing Agents/chemistry , Photosensitizing Agents/pharmacology , Porphyrins/chemistry , Porphyrins/pharmacology , Animals , Biological Transport, Active , Carbohydrates/pharmacokinetics , Cell Line, Tumor , Galectins/chemistry , Galectins/metabolism , Humans , In Vitro Techniques , Mice , Mice, Inbred C3H , Models, Molecular , Molecular Structure , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/metabolism , Photochemotherapy , Photosensitizing Agents/pharmacokinetics , Porphyrins/pharmacokinetics
14.
Dermatol Clin ; 25(1): 5-14, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17126737

ABSTRACT

Aminolevulinic acid photodynamic therapy (ALA-PDT) is an effective and noninvasive therapy for superficial basal cell carcinoma (BCC) and Bowen's disease. It also may have a role in the treatment of nodular BCC and other cutaneous malignancies, including localized cutaneous lymphomas. ALA-PDT offers multiple advantages over traditional treatments, including little to no scarring, excellent cosmetic results, and the ability to treat multiple lesions simultaneously. It is not an effective therapy for aggressive subtypes of BCC or for invasive squamous cell carcinoma. Finally, ALA-PDT may be a useful way to prevent new skin cancers in certain high-risk patients.


Subject(s)
Aminolevulinic Acid/therapeutic use , Photochemotherapy , Photosensitizing Agents/therapeutic use , Skin Neoplasms/drug therapy , Aminolevulinic Acid/adverse effects , Bowen's Disease/drug therapy , Carcinoma, Basal Cell/drug therapy , Carcinoma, Squamous Cell/drug therapy , Humans , Photochemotherapy/adverse effects
16.
Lasers Surg Med ; 38(5): 417-26, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16788928

ABSTRACT

BACKGROUND AND OBJECTIVES: While basal cell carcinoma (BCC) is effectively treated by several methods, many patients with numerous or frequently occurring lesions seek alternatives that can treat multiple cancers, with improved cosmetic outcome. PDT for esophageal and lung carcinomas is approved at a porfimer sodium (Photofrin) dose of 2 mg/kg, but lower doses increase selectivity and decrease both cutaneous phototoxicity and cost. We evaluated low doses of porfimer sodium PDT for treatment of multiple BCC. MATERIALS AND METHODS: Seventy-seven patients with 2,041 BCC were injected with 0.75, 0.875, or 1.0 mg/kg porfimer sodium and treated 2 days later with 630-nm light. Clinical responses were determined at 6 months, then periodically to 5 years. RESULTS: Increasing porfimer sodium dose increased complete responses (CR), with initial CR rates of 72.7% (66-78%, 95% CI), 79.9% (73-86%, 95% CI), and 92.2% (91-93%, 95% CI), albeit with some lower selectivity at the highest dose. At 1 mg/kg, 5-year recurrence rates were 28% (21-35%, 95% CI) and 15% (11-18%, 95% CI) for sporadic and nevoid basal cell carcinoma syndrome (NBCCS) lesions, respectively. CONCLUSIONS: This is the largest dose-ranging study of porfimer sodium, and the largest number of lesions treated in a single study. We found that with 1 mg/kg porfimer sodium, PDT can be a selective and durable treatment for sporadic and NBCCS-associated BCC.


Subject(s)
Carcinoma, Basal Cell/drug therapy , Dihematoporphyrin Ether/administration & dosage , Photochemotherapy/methods , Photosensitizing Agents/administration & dosage , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Treatment Outcome
17.
Lasers Surg Med ; 38(5): 439-44, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16634075

ABSTRACT

BACKGROUND AND OBJECTIVES: Photodynamic therapy (PDT) uses a photosensitizer activated by light, in an oxygen-rich environment, to destroy malignant tumors. Clinical trials of PDT at Roswell Park Cancer Institute (RPCI) use the photosensitizers Photofrin, Photochlor, and 5-ALA-induced protoporphyrin IX (PpIX). In some studies the concentrations of photosensitizer in blood, and occasionally in tumor tissue, were obtained. Pharmacokinetic (PK) data from these individual studies were pooled and analyzed. This is the first published review to compare head-to-head the PK of Photofrin and Photochlor. STUDY DESIGN/MATERIALS AND METHODS: Blood and tissue specimens were obtained from patients undergoing PDT at RPCI. Concentrations of Photofrin, Photochlor, and PpIX were measured using fluorescence analysis. A non-linear mixed effects modeling approach was used to analyze the PK data for Photochlor (up to 4 days post-infusion; two-compartment model) and a simpler multipatient-data-pooling approach was used to model PK data for both Photofrin and Photochlor (at least 150 days post-infusion; three-compartment models). Physiological parameters were standardized to correspond to a standard (70 kg; 1.818 m2 surface area) man to facilitate comparisons between Photofrin and Photochlor. RESULTS: Serum concentration-time profiles obtained for Photofrin and Photochlor showed long circulating half-lives, where both sensitizers could be found more than 3 months after intravenous infusion; however, estimated plasma clearances (standard man) were markedly smaller for Photofrin (25.8 ml/hour) than for Photochlor (84.2 ml/hour). Volumes of distribution of the central compartment (standard man) for both Photofrin and Photochlor were about the size (3.14 L, 4.29 L, respectively) of plasma volume, implying that both photosensitizers are almost 100% bound to serum components. Circulating levels of PpIX were generally quite low, falling below the level of instrument sensitivity within a few days after topical application of 5-ALA. CONCLUSION: We have modeled the PK of Photochlor and Photofrin. PK parameter estimates may, in part, explain the relatively long skin photosensitivity attributed to Photofrin but not Photochlor. Due to the potential impact and limited experimental PK data in the PDT field further clinical studies of photosensitizer kinetics in tumor and normal tissues are warranted.


Subject(s)
Aminolevulinic Acid/pharmacokinetics , Dihematoporphyrin Ether/pharmacokinetics , Photosensitizing Agents/pharmacokinetics , Administration, Topical , Aminolevulinic Acid/analysis , Chlorophyll/analogs & derivatives , Chlorophyll/pharmacokinetics , Dihematoporphyrin Ether/analysis , Fluorometry , Half-Life , Humans , Infusions, Intravenous , Neoplasms/chemistry , Neoplasms/drug therapy , Photosensitizing Agents/analysis
18.
Cancer Chemother Pharmacol ; 57(1): 40-5, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16001178

ABSTRACT

PURPOSE: To measure skin photosensitivity in cancer patients infused with the new second-generation photodynamic sensitizer Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a). A major disadvantage of using the clinically approved photosensitizer Photofrin is potentially prolonged and sometimes severe cutaneous phototoxicity. PATIENTS AND METHODS: Forty-eight patients enrolled in Phases 1 and 2 clinical trials underwent two or more exposures to four graded doses (44.4, 66.6, 88.8 or 133.2 J/cm2) of artificial solar-spectrum light (SSL) before and after administration of Photochlor at a dose of 2.5, 3, 4, 5 or 6 mg/m2 . RESULTS: The most severe skin response, experienced by only six of the subjects, was limited to erythema without edema and could only be elicited by exposure to the highest light dose. Conversely, eight subjects had no discernible reaction to SSL at any light dose. For nearly all the patients, the peak skin response was obtained when the interval between sensitizer injection and exposure to SSL was 1 day and, generally, their sensitivity to SSL decreased with increasing sensitizer-light interval. For example, a 2-day sensitizer-SSL interval resulted in less severe reactions than those obtained with the 1-day interval in 79% of the subjects, while 90% of the subjects exposed to SSL 3 days after Photochlor infusion had responses that were less severe than those obtained with either the 1- or 2-day sensitizer-SSL interval. CONCLUSIONS: Photochlor, at clinically effective antitumor doses, causes only mild skin photosensitivity that declines rapidly over a few days.


Subject(s)
Dihematoporphyrin Ether/adverse effects , Neoplasms/drug therapy , Photochemotherapy , Photosensitivity Disorders/chemically induced , Photosensitizing Agents/adverse effects , Dihematoporphyrin Ether/therapeutic use , Female , Humans , Male , Photosensitizing Agents/therapeutic use , Skin/drug effects , Skin/radiation effects , Ultraviolet Rays
19.
Clin Cancer Res ; 11(11): 4241-50, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15930363

ABSTRACT

PURPOSE: Photodynamic therapy (PDT) is a clinically approved treatment for a variety of solid malignancies. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a potent vascular targeting agent that has been shown to be effective against a variety of experimental rodent tumors and xenografts and is currently undergoing clinical evaluation. We have previously reported that the activity of PDT against transplanted mouse tumors is selectively enhanced by DMXAA. In the present study, we investigated the in vivo tumor vascular responses to the two treatments given alone and in combination. EXPERIMENTAL DESIGN: Vascular responses to (i) four different PDT regimens using the photosensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) at two different fluences (128 and 48 J/cm(2)) and fluence rates (112 and 14 mW/cm(2)), (ii) 5-aminolevulinic acid (ALA)-sensitized PDT (135 J/cm(2) at 75 mW/cm(2)), (iii) DMXAA at a high (30 mg/kg) and low dose (25 mg/kg), and (iv) the combination of HPPH-PDT (48 J/cm(2) at 112 mW/cm(2)) and low-dose DMXAA were studied in BALB/c mice bearing Colon-26 tumors. RESULTS: PDT-induced changes in vascular permeability, determined using noninvasive magnetic resonance imaging with a macromolecular contrast agent, were regimen dependent and did not predict tumor curability. However, a pattern of increasing (4 hours after treatment) and then decreasing (24 hours after) contrast agent concentrations in tumors, seen after high-dose DMXAA or the combination of PDT and low-dose DMXAA, was associated with long-term cure rates of >70%. This pattern was attributed to an initial increase in vessel permeability followed by substantial endothelial cell damage (CD31 immunohistochemistry) and loss of blood flow (fluorescein exclusion assay). Low dose-rate PDT, regardless of the delivered dose, increased the level of magnetic resonance contrast agent in peritumoral tissue, whereas treatment with either DMXAA alone, or PDT and DMXAA in combination resulted in a more selective tumor vascular response. CONCLUSIONS: The observed temporal and spatial differences in the response of tumor vessels to PDT and DMXAA treatments could provide valuable assistance in the optimization of scheduling when combining these therapies. The combination of PDT and DMXAA provides therapeutically synergistic and selective antitumor activity. Clinical evaluation of this combination is warranted.


Subject(s)
Capillary Permeability/drug effects , Neoplasms, Experimental/drug therapy , Photochemotherapy , Xanthones/pharmacology , Aminolevulinic Acid/administration & dosage , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Chlorophyll/administration & dosage , Chlorophyll/analogs & derivatives , Combined Modality Therapy , Dose-Response Relationship, Drug , Immunohistochemistry , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Neoplasms, Experimental/blood supply , Neoplasms, Experimental/pathology , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Platelet Endothelial Cell Adhesion Molecule-1/analysis , Treatment Outcome , Xanthones/therapeutic use
20.
Arch Dermatol ; 141(1): 60-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15655143

ABSTRACT

OBJECTIVE: To report the use of wide-area 5-aminolevulinic acid photodynamic therapy to treat numerous basal cell carcinomas (BCCs) and basaloid follicular hamartomas (BFHs). DESIGN: Report of cases. SETTING: Roswell Park Cancer Institute. Patients Three children with BCCs and BFHs involving 12% to 25% of their body surface areas. Interventions Twenty percent 5-aminolevulinic acid was applied to up to 22% of the body surface for 24 hours under occlusion. A dye laser and a lamp illuminated fields up to 7 cm and 16 cm in diameter, respectively; up to 36 fields were treated per session. MAIN OUTCOME MEASURES: Morbidity, patient response, and light dose-photodynamic therapy response relationship and durability. RESULTS: Morbidity was minimal, with selective phototoxicity and rapid healing. After 4 to 7 sessions, with individual areas receiving 1 to 3 treatments, the patients had 85% to 98% overall clearance and excellent cosmetic outcomes without scarring. For laser treatments, a sigmoidal light dose-response relationship predicted more than 85% initial response rates for light doses 150 J/cm(2) or more. Responses were durable up to 6 years. Conclusion 5-Aminolevulinic acid photodynamic therapy is safe, well tolerated, and effective for extensive areas of diffuse BCCs and BFHs and appears to be the treatment of choice in children.


Subject(s)
Aminolevulinic Acid/therapeutic use , Basal Cell Nevus Syndrome/drug therapy , Hamartoma Syndrome, Multiple/drug therapy , Photochemotherapy , Photosensitizing Agents/therapeutic use , Skin Neoplasms/drug therapy , Adolescent , Aminolevulinic Acid/adverse effects , Basal Cell Nevus Syndrome/pathology , Child , Female , Hamartoma Syndrome, Multiple/pathology , Humans , Male , Photochemotherapy/adverse effects , Photosensitizing Agents/adverse effects , Skin Neoplasms/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...